文献速递脑血管病认知障碍与痴呆

COVID-19住院后12个月神经功能恢复轨迹:一项前瞻性纵向研究

Trajectories of Neurologic Recovery 12 Months After Hospitalization for COVID-19: A Prospective Longitudinal Study.
PubMed 文献 · Neurology · 2022-03-21

该前瞻性纵向队列研究纳入2020年3月10日至5月20日因COVID-19住院的患者,在发病后6个月和12个月进行电话随访。12个月时87%的患者至少一项功能、认知或Neuro-QoL指标异常,认知异常在无痴呆/认知异常病史者中持续存在达50%。住院期间有无神经系统并发症者的12个月mRS无显著差异,但认知和焦虑评分在6至12个月间显著改善。

要点

  • 12个月时87%(197/227)的患者至少一项指标异常,mRS>0者占75%。
  • 住院期间有无神经系统并发症者的12个月mRS无显著差异(调整OR 1.4,95%CI 0.8-2.5)。
  • 6至12个月间t-MoCA和焦虑评分显著改善,分别有56%和45%的患者改善。

核心结论

  • 重症COVID-19住院后12个月,87%的患者功能、认知或Neuro-QoL指标持续异常,无痴呆/认知异常病史者中50%认知异常持续存在。
  • 住院期间有无神经系统并发症者仅疲劳严重程度存在显著差异,12个月mRS无显著差异。
  • 6至12个月间认知(t-MoCA)和焦虑(Neuro-QoL)评分分别有56%和45%的患者显著改善。
  • 作者指出结果可能不适用于轻或中度COVID-19患者。

研究设计与样本

  • 前瞻性纵向队列研究,纳入2020年3月10日至5月20日因COVID-19住院的患者,包括住院期间有或无神经系统并发症者。
  • 在COVID-19发病后6个月和12个月进行电话随访评估。
  • 12个月随访完成242例(中位年龄65岁,64%男性,34%住院期间插管),174例完成6个月和12个月两次随访。
  • 主要结局为12个月改良Rankin量表(mRS)评分,采用多变量序数分析比较有或无神经系统并发症的患者。
  • 次要结局包括日常生活活动能力(Barthel指数)、电话蒙特利尔认知评估(t-MoCA)以及神经疾病生活质量(Neuro-QoL)焦虑、抑郁、疲劳和睡眠评估。

主要发现

  • 12个月时197/227(87%)至少一项指标异常:mRS>0(75%)、Barthel指数<100(64%)、t-MoCA≤18(50%)、高焦虑(7%)、抑郁(4%)、疲劳(9%)、睡眠差(10%)。
  • 调整年龄、性别、种族、COVID-19前mRS和插管状态后,住院期间有神经系统并发症者(n=113)与无并发症者(n=129)的12个月mRS评分无显著差异(调整OR 1.4,95%CI 0.8-2.5)。
  • 有神经系统并发症者疲劳评分更高(T评分47 vs 44;p=0.037)。
  • 6至12个月间t-MoCA评分显著改善(56%改善,中位差值1分;p=0.002),Neuro-QoL焦虑评分显著改善(45%改善;p=0.003)。
  • 疲劳、睡眠和抑郁评分分别有48%、48%和38%的患者出现非显著性改善;Barthel指数和mRS评分在6至12个月间超过50%的患者保持不变。

局限性

  • 作者指出结果可能不适用于轻或中度COVID-19患者。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND OBJECTIVE: Little is known about trajectories of recovery 12 months after hospitalization for severe COVID-19. METHODS: We conducted a prospective, longitudinal cohort study of patients with and without neurologic complications during index hospitalization for COVID-19 from March 10, 2020, to May 20, 2020. Phone follow-up batteries were performed at 6 and 12 months after COVID-19 onset. The primary 12-month outcome was the modified Rankin Scale (mRS) score comparing patients with or without neurologic complications using multivariable ordinal analysis. Secondary outcomes included activities of daily living (Barthel Index), telephone Montreal Cognitive Assessment (t-MoCA), and Quality of Life in Neurologic Disorders (Neuro-QoL) batteries for anxiety, depression, fatigue, and sleep. Changes in outcome scores from 6 to 12 months were compared using nonparametric paired-samples sign test. RESULTS: Twelve-month follow-up was completed in 242 patients (median age 65 years, 64% male, 34% intubated during hospitalization) and 174 completed both 6- and 12-month follow-up. At 12 months, 197/227 (87%) had ≥1 abnormal metric: mRS >0 (75%), Barthel Index <100 (64%), t-MoCA ≤18 (50%), high anxiety (7%), depression (4%), fatigue (9%), or poor sleep (10%). Twelve-month mRS scores did not differ significantly among those with (n = 113) or without (n = 129) neurologic complications during hospitalization after adjusting for age, sex, race, pre-COVID-19 mRS, and intubation status (adjusted OR 1.4, 95% CI 0.8-2.5), although those with neurologic complications had higher fatigue scores (T score 47 vs 44; p = 0.037). Significant improvements in outcome trajectories from 6 to 12 months were observed in t-MoCA scores (56% improved, median difference 1 point; p = 0.002) and Neuro-QoL anxiety scores (45% improved; p = 0.003). Nonsignificant improvements occurred in fatigue, sleep, and depression scores in 48%, 48%, and 38% of patients, respectively. Barthel Index and mRS scores remained unchanged between 6 and 12 months in >50% of patients. DISCUSSION: At 12 months after hospitalization for severe COVID-19, 87% of patients had ongoing abnormalities in functional, cognitive, or Neuro-QoL metrics and abnormal cognition persisted in 50% of patients without a history of dementia/cognitive abnormality. Only fatigue severity differed significantly between patients with or without neurologic complications during index hospitalization. However, significant improvements in cognitive (t-MoCA) and anxiety (Neuro-QoL) scores occurred in 56% and 45% of patients, respectively, between 6 and 12 months. These results may not be generalizable to those with mild or moderate COVID-19.

来源:Neurology,查看原文。版权归原作者所有。

引用

  1. Frontera JA, Yang D, Medicherla C, et al. Trajectories of Neurologic Recovery 12 Months After Hospitalization for COVID-19: A Prospective Longitudinal Study. Neurology. 2022. PMID: 35314503. doi:10.1212/WNL.0000000000200356

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。